Citius Pharmaceuticals reported its third quarter 2026 results, highlighted by the continued commercial ramp of LYMPHIR, which generated $1.5 million in quarterly revenue. The company is transitioning into a commercial-stage entity, expanding its oncology field force to 29 professionals to support nationwide deployment and formulary adoption.
Key Highlights
- Institutional vial orders for LYMPHIR grew 31% during the quarter, with 383 vials ordered in July 2026 alone, marking the highest monthly volume since launch.
- Quarterly gross profit reached $1.0 million, representing a 67% margin, while the nine-month margin remains higher at 77%.
- Liquidity improved to $17.0 million in cash as of June 30, 2026, supported by $9.7 million in warrant exercise proceeds and a $4.5 million direct offering.